Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTRV NASDAQ:HSTO NASDAQ:SCPS NYSE:UPC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTRVContraVir Pharmaceuticals$0.04+16.0%$3.11$3.52▼$91.00$35K1.16432,822 shs108,443 shsHSTOHistogen$0.02-29.0%$0.02$0.05▼$0.55$96K1.1910,369 shs208 shsSCPSScopus BioPharma$0.00$0.00$0.00▼$0.01$13K-0.191,987 shs10 shsUPCUniverse Pharmaceuticals$3.27-7.9%$4.30$2.51▼$2,418.00$141K1.43177,767 shs27,039 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTRVContraVir Pharmaceuticals-22.39%-28.02%-51.50%-88.36%-96.53%HSTOHistogen-9.69%+10,466.67%+3,070.00%+9.31%-84.90%SCPSScopus BioPharma0.00%0.00%-97.00%0.00%+50.00%UPCUniverse Pharmaceuticals-4.31%-5.84%-10.58%-0.28%-99.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTRVContraVir PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AHSTOHistogenN/AN/AN/AN/AN/AN/AN/AN/ASCPSScopus BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AUPCUniverse PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTRVContraVir Pharmaceuticals 0.00N/AN/AN/AHSTOHistogen 0.00N/AN/AN/ASCPSScopus BioPharma 0.00N/AN/AN/AUPCUniverse Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTRVContraVir PharmaceuticalsN/AN/AN/AN/A$0.80 per shareN/AHSTOHistogen$19K7.12N/AN/A$3.13 per share0.01SCPSScopus BioPharmaN/AN/AN/AN/AN/AN/AUPCUniverse Pharmaceuticals$19.29M0.01N/AN/A$163.50 per share0.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTRVContraVir Pharmaceuticals-$9.45MN/A0.00∞N/AN/A-4,810.77%-130.14%N/AHSTOHistogen-$10.62M-$2.81N/A∞N/AN/AN/AN/AN/ASCPSScopus BioPharma-$11.61MN/A0.00∞N/AN/AN/AN/AN/AUPCUniverse Pharmaceuticals-$6.16MN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTRVContraVir PharmaceuticalsN/AN/AN/AN/AN/AHSTOHistogenN/AN/AN/AN/AN/ASCPSScopus BioPharmaN/AN/AN/AN/AN/AUPCUniverse PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTRVContraVir PharmaceuticalsN/A0.550.55HSTOHistogenN/AN/AN/ASCPSScopus BioPharmaN/AN/AN/AUPCUniverse PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTRVContraVir Pharmaceuticals1.07%HSTOHistogenN/ASCPSScopus BioPharmaN/AUPCUniverse Pharmaceuticals0.18%Insider OwnershipCompanyInsider OwnershipCTRVContraVir Pharmaceuticals1.60%HSTOHistogen3.30%SCPSScopus BioPharma5.10%UPCUniverse Pharmaceuticals57.38%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTRVContraVir Pharmaceuticals14800,000N/ANot OptionableHSTOHistogen204.27 millionN/ANot OptionableSCPSScopus BioPharma942.08 million39.94 millionNot OptionableUPCUniverse Pharmaceuticals22043,000731,000Not OptionableCTRV, UPC, HSTO, and SCPS HeadlinesRecent News About These CompaniesPharma Playbook: What Practitioners Can Learn from Early UPC LitigationMay 14, 2025 | ipwatchdog.comIUniverse Pharmaceuticals Reports Full Year 2024 EarningsMay 3, 2025 | finance.yahoo.comUniverse Pharmaceuticals INC Announces Share Consolidation Effective March 24, 2025March 20, 2025 | quiverquant.comQUniverse Pharmaceuticals INC Announces Share ConsolidationMarch 20, 2025 | gurufocus.comUniverse Pharmaceuticals INC Announces Share ConsolidationMarch 20, 2025 | investing.comUniverse Pharmaceuticals INC Announces Share ConsolidationMarch 20, 2025 | globenewswire.comUniverse Pharmaceuticals Approves Share Consolidation at Extraordinary MeetingMarch 11, 2025 | tipranks.comUniverse Pharmaceuticals INC Faces Potential Delisting from Nasdaq Due to Delinquent Annual Report FilingFebruary 25, 2025 | quiverquant.comQUniverse Pharmaceuticals INC Receives Staff Determination Notice from Nasdaq Related to Delayed Annual ReportFebruary 25, 2025 | globenewswire.comUniverse Pharmaceuticals proposes revised share consolidationFebruary 11, 2025 | msn.comUniverse Pharmaceuticals (NASDAQ:UPC) Stock, Short Interest ReportFebruary 10, 2025 | benzinga.comUniverse Pharmaceuticals INC.: Universe Pharmaceuticals INC Receives Nasdaq Delisting Notice Subject to Hearing RequestFebruary 6, 2025 | finanznachrichten.deUPC’s Unexpected Plunge: What’s Next?February 5, 2025 | bovnews.comBUniverse Pharmaceuticals gets Nasdaq delisting noticeFebruary 4, 2025 | markets.businessinsider.comUniverse Pharmaceuticals INC Faces Nasdaq Delisting Due to Low Share PriceFebruary 3, 2025 | quiverquant.comQUniverse Pharmaceuticals INC Receives Nasdaq Delisting Notice Subject to Hearing RequestFebruary 3, 2025 | globenewswire.comUniverse Pharmaceuticals announces shareholder meetingJanuary 30, 2025 | msn.comUniverse Pharmaceuticals stock hits 52-week low at $0.48 amid steep declineJanuary 29, 2025 | msn.comUniverse Pharmaceuticals Inc (UPC) Stock: A Deeper Look at Its True PotentialDecember 29, 2024 | bovnews.comBUniverse Pharmaceuticals Files Registration for 37.5 Million SharesDecember 14, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Stocks to Buy Ahead of the Upcoming Earnings SeasonBy Chris Markoch | July 11, 2025View 3 Stocks to Buy Ahead of the Upcoming Earnings Season3 Biotech Stocks to Watch: Iovance, Neurocrine & VikingBy Chris Markoch | June 29, 2025View 3 Biotech Stocks to Watch: Iovance, Neurocrine & VikingAlphabet: Technical Momentum Is Starting to TurnBy Ryan Hasson | July 10, 2025View Alphabet: Technical Momentum Is Starting to TurnCyclical Rebound or False Start for These 3 Stocks?By Gabriel Osorio-Mazilli | July 17, 2025View Cyclical Rebound or False Start for These 3 Stocks?CTRV, UPC, HSTO, and SCPS Company DescriptionsContraVir Pharmaceuticals NASDAQ:CTRVContraVir Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. It engages in the development of TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B; and CRV431, a novel drug candidate for the treatment of chronic HBV infection. The company was founded in 2013 and is headquartered in Edison, New Jersey.Histogen NASDAQ:HSTO$0.02 -0.01 (-29.02%) As of 07/17/2025Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases. Histogen Inc. was founded in 2007 and is based in San Diego, California. On April 18, 2024, Histogen Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of California.Scopus BioPharma NASDAQ:SCPS$0.0003 0.00 (0.00%) As of 07/17/2025Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.Universe Pharmaceuticals NYSE:UPC$3.27 -0.28 (-7.89%) Closing price 03:59 PM EasternExtended Trading$3.42 +0.16 (+4.74%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was founded in 1998 and is based in Ji'An, China. Universe Pharmaceuticals INC operates as a subsidiary of Sununion Holding Group Limited. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
